Cho Hyun-Jai, Lee Juyong, Wecker Andrea, Yoon Young-sup
Caritas St. Elizabeth's Medical Center, Division of Cardiovascular Research, Tufts University School of Medicine, Boston, Massachusetts 02135, USA.
Regen Med. 2006 May;1(3):337-45. doi: 10.2217/17460751.1.3.337.
Since the first experiments of cell transplantation into the heart were performed in the early 1990s, the identification of adult stem cells has triggered attempts to regenerate damaged heart tissue by cellular transplantation. Until recently, a multitude of adult stem or progenitor cells from various tissues have been proposed to meet this end. Bone marrow in particular has emerged as the most promising source for stem and progenitor cells because, besides being the organ of hematopoietic maintenance, it contains a complex assortment of stem and progenitor cells. A large body of provocative experimental evidence for vascular and myocardial regeneration by these cells has generated further enthusiasm for their use. However, many questions remain unanswered in this new field of research regarding the therapeutic potential and the mechanisms responsible for the observed therapeutic effects. In this review, the authors discuss the therapeutic capacity of currently available representative bone marrow-derived stem and progenitor cells for treating ischemic heart diseases.
自20世纪90年代初首次进行细胞移植入心脏的实验以来，成体干细胞的鉴定引发了通过细胞移植来再生受损心脏组织的尝试。直到最近，人们提出了多种来自不同组织的成体干细胞或祖细胞来实现这一目标。骨髓尤其已成为干细胞和祖细胞最有前景的来源，因为除了是维持造血的器官外，它还包含各种各样的干细胞和祖细胞。大量关于这些细胞促进血管和心肌再生的具有启发性的实验证据，进一步激发了人们对其应用的热情。然而，在这个新的研究领域中，关于治疗潜力以及导致观察到的治疗效果的机制，仍有许多问题未得到解答。在这篇综述中，作者讨论了目前可用的具有代表性的骨髓来源的干细胞和祖细胞治疗缺血性心脏病的治疗能力。
